On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies

Author:

Calinescu Andreea12ORCID,Turcu Gabriela123,Nedelcu Roxana I.134ORCID,Brinzea Alice14,Hodorogea Anastasia12ORCID,Antohe Mihaela13,Diaconu Carmen5,Bleotu Coralia5,Pirici Daniel6ORCID,Jilaveanu Lucia B.7,Ion Daniela A.1,Badarau Ioana A.1

Affiliation:

1. Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

2. Dermatology 1 Department, Colentina Clinical Hospital, 020125 Bucharest, Romania

3. Derma 360° Clinic, 011273 Bucharest, Romania

4. National Institute for Infectious Diseases Prof. Dr. Matei Balș, 021105 Bucharest, Romania

5. Stefan Nicolau Institute of Virology, 030304 Bucharest, Romania

6. University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania

7. Department of Medicine, Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 208028, USA

Abstract

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein belonging to the carcinoembryonic antigen (CEA) family that is expressed on a wide variety of cells and holds a complex role in inflammation through its alternate splicing and generation of various isoforms, mediating intricate mechanisms of modulation and dysregulation. Initially regarded as a tumor suppressor as its expression shows considerable downregulation within the epithelia in the early phases of many solid cancers, CEACAM1 has been linked lately to the progression of malignancy and metastatic spread as various papers point to its role in tumor progression, angiogenesis, and invasion. We reviewed the literature and discussed the various expression patterns of CEACAM1 in different types of tumors, describing its structure and general biologic functions and emphasizing the most significant findings that link this molecule to poor prognosis. The importance of understanding the role of CEACAM1 in cell transformation stands not only in this adhesion molecule’s value as a prognostic factor but also in its promising premise as a potential new molecular target that could be exploited as a specific cancer therapy.

Funder

Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii

Publisher

Hindawi Limited

Subject

Immunology,General Medicine,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3